Chiesi to Buy KalVista for $1.9 Billion in Its Biggest-Ever Deal, Wrapping the First Oral HAE Pill Into a Growing Rare Disease Portfolio
Italian drugmaker Chiesi will pay $27 a share for KalVista Pharmaceuticals to acquire Ekterly, the first oral on-demand treatment for hereditary angioedema, in a deal expected to close in the third quarter.
4 min read4 sources